A closer look at Canada's homegrown COVID-19 vaccine candidates
Scientists across Canada are using a range of technologies, from more traditional protein subunit vaccines to newer technologies such as replicating viral vector and DNA vaccines to produce immunity against SARS-CoV-2.
October 19, 2020
Coronavirus antibodies last at least three months after infection, study suggests
October 8, 2020
Key members of the ONCoV Genomics Coalition, Samira Mubareka and Andrew McArthur conducted a collaborative study that shows antibodies to SARS-CoV-2 can be detected in serum and saliva for > 3 months post-symptom onset. This research may be useful in monitoring immune responses in individuals & therefore, vaccine development.
Infectious disease expert urges public to trust the science
October 8, 2020
Kingston’s top infectious disease expert is asking the public to start trusting COVID-19-related science and the statistics. “We started off way back in the winter and spring with precautionary principles around a lot of things. Now we’ve learned lots and lots about the virus, so we can now apply evidence,” Dr. Gerald Evans, medical director of infection control at Kingston Health Sciences Centre.
Songbird flying high with Health Canada approval of double biomarker COVID-19 test device
October 2, 2020
Health Canada has approved a portable COVID-19 test kit which began as a testing regime for identifying pathogens, microbes and viruses in the European food and natural products industry. The Hyris Bcube developed by Guelph, Ontario-based Songbird Life Science Inc., in partnership with London, U.K.’s Hyris Ltd., is described as a portable DNA-based “laboratory in a box” for coronavirus testing in large urban spaces as well as more remote, indigenous communities in Canada’s north.
Canada's Bio-Revolution 2020 Webinar Series. "Editing our Economic Future: The Power of CRISPR”
September 28, 2020
A conversation between Gairdner Foundation laureates and leading Canadian researchers on using the opportunities and applications of gene editing, specifically by using CRISPR/Cas9, to transform multiple sectors, from therapeutics to diagnostics, agriculture, and low carbon manufacturing, all of which have a profound impact on our economy.
How Biotech is Changing the Way We Make Stuff
September 24, 2020
Dr. Bettina Hamelin, President & CEO, Ontario Genomics, discusses how increased federal funding for engineering biology could give Canada an edge on innovative manufacturing initiatives to spur economic recovery & create homegrown jobs.
Government of Canada: Policy Statement on Research Security and COVID-19
September 14, 2020
The Government of Canada is encouraging all members of the research ecosystem to be aware of the potential risks to their work and asking them to take appropriate measures to protect their knowledge creation and innovations, all while maintaining a strong commitment to Open Science and support for a global research response to the COVID-19 pandemic.
Predicting the recombination potential of severe acute respiratory syndrome coronavirus 2 and Middle East respiratory syndrome coronavirus
Key members of the ONCoV Genomics Coalition, Samira Mubareka and Andrew McArthur conducted a collaborative study analyzing and predicting the recombination potential of SARS-CoV-2 and the Middle East respiratory syndrome coronavirus.
September 9, 2020
A Comparison of Whole Genome Sequencing of SARS-CoV-2 Using Amplicon-Based Sequencing, Random Hexamers, and Bait Capture
Three key members of the ONCoV Genomics Coalition, Bo Wang, Andrew McArthur, and Samira Mubareka conducted a study analyzing different genomic sequencing methods to understand which protocol works better for sequencing SARS-CoV-2.
August 17, 2020
ONCoV members funded through phase 2 of Ontario’s COVID-19 Rapid Research Fund
July 29, 2020
The Ontario Government announced phase two of funding for a number of research projects aimed at fighting COVID-19. The projects are a part of $20 million in funding that the Government has put towards the Ontario COVID-19 Rapid Research Fund, which focuses on research into “vaccine development, diagnostics, drug trials and development, and social sciences.”
Genetic detectives begin work to trace spread of COVID-19 in Canada
July 12, 2020
“Knowing how the virus spread will show where there were weaknesses in public health measures early on”, said Dr. Andrew McArthur, Director, biomedical discovery & commercialization at McMaster University and a key member of the ONCoV Genomics Coalition.
McMaster researcher traces spread of COVID-19 in Canada
July 12, 2020
One of the key members of the ONCoV Genomics Coalition Dr. Andrew McArthur, Director, biomedical discovery & commercialization at McMaster University is working on deducing how we tackled the COVID-19 pandemic and and what we can do to improve our response in future pandemics.
A simple protein-based SARS-CoV-2 surrogate neutralization assay
July 11, 2020
With the pandemic surpassing 12M confirmed cases & 550K deaths worldwide (by July 11, 2020), defining key components of immune response to SARS-CoV-2 is critical. Members of ONCoV Genomics Coalition Allison McGeer & Samira Mubareka are a part of the research team.
Genomics in the battle against COVID-19
June 1, 2020
Genomics plays an important role in COVID-19 research, from detecting infections and understanding how the virus mutates, to tracking these mutations and developing vaccines and treatments. Watch our two animated videos: On the Trail of Covid-19 & The Race for a Cure
Understanding a Disease – COVID-19 and Genomics Canada Podcast
June 1, 2020
COVID-19 is a virus that impacts different individuals in similar ways. In this podcast, Dr. Bettina Hamelin, President & CEO of Ontario Genomics and Dr. Rob Annan, President & CEO of Genome Canada explore the scientific aspects of COVID-19 dynamics and how it affects individuals.
Hospital News: Dr. Samira Mubareka - It’s all in the genome: Preparing for the next waves of COVID-19
May 28, 2020
On January 24th, Sunnybrook Health Sciences admitted the first Canadian patient with COVID-19. The traveller had just returned from Wuhan, China, the epicentre of the virus outbreak. He presented with a respiratory illness due to SARS-CoV-2, the coronavirus that causes COVID-19. At that moment I realized this virus would come to dominate our reality, both at Sunnybrook and across Canada.
COVID-19 Research: Genomics, Rapid Execution & Funding featuring Samira Mubareka
Ontario’s infectious disease expert speaks about her COVID-19 research in an interview with TheFuturEconomy.ca. Leading Sunnybrook’s Coronavirus response, her work on isolating & understanding the virus is helping roll out rapid research efforts.
April 27, 2020
Genome Canada leads $40 million genomics initiative to address COVID-19 pandemic
Important new pan-Canadian Genomics partnership with $40M investment – CanCOGeN, a multi-pronged national approach to harnessing robust genomic solutions to meet the COVID-19 challenge head-on.
April 23, 2020
Canadian bioscience firm says it’s approved for production of rapid COVID-19 testing device
Ontario-made rapid COVID-19 genomics technology from Spartan Bio received approval for frontline use. This quick and portable innovation significantly expands Canada’s testing capacity.
April 12, 2020
McMaster researchers awarded $1.475M to further investigate COVID-19
November 6, 2020
A team of McMaster researchers has been awarded $1.475M from the federal government to further investigate COVID-19. Overall, the fund will provide close to $28M for 79 projects at 52 universities, research hospitals, colleges, polytechnics and Cégeps across Canada
Consortium Secures $5M to Expand Genomics Platform for COVID Research
December 1, 2020
A national consortium led by DNAstack will expand development of a software platform for genomics and health data and apply it to COVID-19. The $5.1M project, called COVID Cloud, is co-funded by Canada’s Digital Technology Supercluster and aims to increase Canada’s capacity to harness exponentially growing volumes of genomics and biomedical data to advance precision health.